On May 24, 2021, biopharmaceutical company NeoImmuneTech, Inc. shared that the first patient was dosed in a pilot study centered around NT-I7 (efineptakin alfa). Altogether, the study is designed…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
